Combination treatment for liver cancer confined to the right side
Part of Cancer clinical trials.
This trial tests a combination of a liver-directed radiation therapy, a chemoembolization procedure that targets the tumor, and two immunotherapy/anti-angiogenesis drugs (Tislelizumab and Lenvatinib) to see if it is safe and effective for people whose liver cancer is only in the right lobe and cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of liver cancer (hepatocellular carcinoma) that has not spread beyond the right side of your liver.
- Your liver function must be at least moderately preserved (Child-Pugh score A or early B).
- You must be able to care for yourself (ECOG performance status 0 or 1).
- Your vital organs (bone marrow, liver, kidneys) must be working well enough to safely receive the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a combination treatment for liver cancer that can be surgically removed but has started growing into nearby blood vessels. The goal is to see if the combination helps control the disease before or after surgery.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
Hear when a new Initially Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.